ストックスクリーナーアプリを入手
36.06
1.03%
-0.4556
前日終値:
$36.52
開ける：
$37.32
24時間の取引高:
5.65M
Relative Volume:
2.16
時価総額：
$6.17B
収益：
$1.64B
当期純損益:
$121.85M
株価収益率:
23.42
EPS:
1.54
ネットキャッシュフロー:
$-480.40M
1週間 パフォーマンス:
-43.09%
1か月 パフォーマンス:
-35.05%
6か月 パフォーマンス:
-70.28%
1年 パフォーマンス:
-72.68%
1日の値動き範囲:
$36.04
$39.66
1週間の範囲:
$35.46
$64.80
52週間の値動き範囲:
$35.46
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
SRPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
36.13 | 6.17B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.12 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
530.05 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
550.61 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.09 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.12 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-11 | 開始されました | Wells Fargo | Overweight |
| 2025-04-02 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-11-27 | 繰り返されました | Needham | Buy |
| 2024-11-25 | 開始されました | H.C. Wainwright | Sell |
| 2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
These 3 Biotech Picks Can Combat Sarepta Losses After Unexpected Death - TheStreet Pro
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta ... - Bluefield Daily Telegraph
Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? - Yahoo Finance
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference | SRPT Stock News - GuruFocus
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference - Business Wire
Sarepta Therapeutics (SRPT) Faces Investment Rating Downgrade - GuruFocus
Sarepta price target lowered to $125 from $183 at Needham - Yahoo Finance
Sarepta Therapeutics (SRPT) Price Target Lowered by Wells Fargo | SRPT Stock News - GuruFocus
UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating - marketscreener.com
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot - simplywall.st
Evercore ISI cuts Sarepta stock rating, slashes price target - Investing.com
Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Sarepta (SRPT) Downgraded by Evercore ISI with New Price Target | SRPT Stock News - GuruFocus
Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday - Insider Monkey
Beware of Sarepta, CRISPR Therapeutics, and More - Baystreet.ca
Long-Term Potential and Strategic Developments Drive Buy Rating for Sarepta Therapeutics Despite Short-Term Challenges - TipRanks
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT) - Yahoo Finance
Sarepta Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment - insights.citeline.com
Some unshod by Prasad nod as CBER change socks stocks - BioWorld MedTech
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low - Investor's Business Daily
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating - Seeking Alpha
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why - Yahoo Finance
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up - Benzinga
BMO Capital cuts Sarepta stock target to $120, maintains Outperform - Investing.com
Cantor Fitzgerald cuts Sarepta stock target to $81 - Investing.com
Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (NASDAQ:SRPT) - Seeking Alpha
TD Cowen cuts Sarepta stock target, maintains Buy rating - Investing.com
Sarepta stock plummets as lower sales outlook adds to gloom over FDA’s new biologics hire - BioPharma Dive
Sarepta (SRPT) Target Price Lowered by Needham Amid Leadership Change Concerns | SRPT Stock News - GuruFocus
Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire. - MSN
Sarepta Therapeutics (SRPT) Price Target Reduced by Piper Sandler | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT): Analyst Lowers Price Target but Maintains Rating | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Revised by Cantor Fitzgerald | SRPT Stock News - GuruFocus
Sarepta (SRPT) Price Target Cut by RBC Capital Amid Elevidys Challenges | SRPT Stock News - GuruFocus
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Sarepta Therapeutics (SRPT) Sees Price Target Reduced by Analyst | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by Morgan Stanley | SRPT Stock News - GuruFocus
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results - Benzinga
Sarepta Therapeutics (SRPT) Price Target Lowered by Needham Analyst | SRPT Stock News - GuruFocus
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2025 Earnings Call Transcript - Insider Monkey
Sarepta (SRPT) Faces Price Target Reduction Amid Revenue Challenges | SRPT Stock News - GuruFocus
Sarepta stock target cut to $40 by H.C. Wainwright on slow sales - Investing.com
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Sarepta (SRPT) Target Price Reduced Amid Regulatory Concerns | SRPT Stock News - GuruFocus
Guggenheim Adjusts Sarepta (SRPT) Price Target Amid Uncertainty | SRPT Stock News - GuruFocus
S&P 500 Futures Rise in Premarket Trading; Sarepta Therapeutics, OneStream Lag - Barron's
Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales - Yahoo Finance
Sarepta (SRPT) Price Target Reduced by Morgan Stanley Amid Elevidys Sales Challenges | SRPT Stock News - GuruFocus
Sarepta (SRPT) Faces Target Price Cut Amid Revenue Miss and Regulatory Concerns | SRPT Stock News - GuruFocus
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
2.11%
0.83%
大文字化:
|
ボリューム (24 時間):